Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a Phase 3 clinical study titled ‘A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS).’ The study aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of two dosing options of dulaglutide in children aged 10 to less than 18 years with Type 2 Diabetes Mellitus. This study is significant as it explores additional treatment options for managing pediatric diabetes, a growing health concern.
The intervention being tested is dulaglutide, an injectable drug administered subcutaneously. It is designed to improve blood sugar control in pediatric patients with Type 2 Diabetes.
This open-label, single-arm study involves a single group of participants receiving the experimental treatment, with no masking involved. The primary purpose is to assess treatment efficacy and safety.
The study began on January 10, 2025, with recruitment currently ongoing. The last update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progression and timelines for potential results.
This update could positively influence Eli Lilly’s stock performance by showcasing their commitment to expanding treatment options in the pediatric diabetes market. Investors may view this as a strategic move to capture a niche market segment, potentially boosting investor confidence. Competitors in the diabetes treatment space will likely monitor these developments closely.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.